Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

Post-Marketing Surveillance Study Micardis® Plus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02242357

Enrollment

14553

Registered

2014-09-17

Start date

2003-01-31

Completion date

Unknown

Last updated

2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Study to evaluate efficacy and tolerability of Micardis®/Micardis® Plus under usual daily-practice prescribing conditions in hypertensive patients

Interventions

DRUGMicardis®

DRUGMicardis® Plus

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Males and females for whom a medical antihypertensive therapy is indicated * Age \>= 18 years

Exclusion criteria

* Age \< 18 years

Design outcomes

Primary

Measure	Time frame
Change in morning blood pressure (office and self-measured)	up to 6 weeks

Secondary

Measure	Time frame
Change in heart rate	up to 6 weeks
Number of patients with adverse drug reactions	up to 6 weeks
Assessment of efficacy by investigator on a 5-point scale	at week 6
Assessment of tolerability by investigator on 5-point scale	at week 6
Change in rate of morning complaints	up to 6 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026